Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

Prostate Cancer Clinical Trial

Official title:

Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01025479
• Other study ID #: NIS-OKR-CAS-2009/1
• Status: Completed
• Phase: N/A
• First received: December 1, 2009
• Last updated: June 28, 2010
• Start date: November 2009
• Est. completion date: March 2010

Study information

• Verified date: June 2010
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Recruitment information / eligibility

• Status: Completed
• Enrollment: 829
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• pathologic confirmation of prostate cancer

• patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion Criteria:

• patients who are hard to be analysed by limitation of chart record according to investigators'discretion

• patients who already have been registered in this study

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Osteoporosis
• Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
Korea, Republic of	Research Site	Cheonan-si	Chungcheongnam-do
Korea, Republic of	Research Site	Cheongju-si	Chungcheongbuk-do
Korea, Republic of	Research Site	Chungju-si	Chungcheongbuk-do
Korea, Republic of	Research Site	Daegu
Korea, Republic of	Research Site	Daejeon
Korea, Republic of	Research Site	Gangneung-si	Gangwon-do
Korea, Republic of	Research Site	Goyang-si	Gyeonggi-do
Korea, Republic of	Research Site	Gumi-si	Gyeongsangbuk-do
Korea, Republic of	Research Site	Guri-si	Gyeonggi-do
Korea, Republic of	Research Site	Gwangju
Korea, Republic of	Research Site	Gyeongju-si	Gyeongsangbuk-do
Korea, Republic of	Research Site	Iksan-si	Jeollabuk-do
Korea, Republic of	Research Site	Incheon
Korea, Republic of	Research Site	Jeju
Korea, Republic of	Research Site	Masan-si	Gyeongsangnam-do
Korea, Republic of	Research Site	Pusan
Korea, Republic of	Research Site	Seoul
Korea, Republic of	Research Site	Ulsan

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.
Secondary	To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.